One of the first two vaccines being tested in patients to fight the coronavirus comes from a Chinese company, CanSino Biologics, that Qiming Venture has invested in.
The vaccine that's been developed joins the human trials initiated in Seattle to fight the disease caused by the coronavirus infection. This is China's first COVID-19 vaccine candidate entering the clinical research phase.
As Qiming partner Helen Wong explained it, the cross-border venture firm led the pre-revenue company's Series B financing in 2015 and participated in the next funding round in 2017. The Chinese biotech company became the first vaccine stock to be listed on the Main Board of the Hong Kong Stock Exchange in 2019.
The vaccine, co-developed by the Hong Kong-listed company and China's Academy of Military Medical Sciences, will undergo clinical trials in Wuhan, the original epicenter of the outbreak.
Here's more info on how several Qiming portfolio companies are fighting the coronavirus outbreak.
The vaccine, co-developed by the Hong Kong-listed company and China's Academy of Military Medical Sciences, will undergo clinical trials in Wuhan, the original epicenter of the outbreak.
Here's more info on how several Qiming portfolio companies are fighting the coronavirus outbreak.
